Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines

[1]  A. Ballestrero,et al.  Dose-dense Vinorelbine and Paclitaxel with Granulocyte Colony-stimulating Factor in Metastatic Breast Cancer Patients: Anti-tumor Activity and Peripheral Blood Progenitor Cell Mobilization Capability , 2003, Breast Cancer Research and Treatment.

[2]  M. Piccart,et al.  Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. , 2003, European journal of cancer.

[3]  M. Piccart,et al.  Chemotherapy for metastatic breast cancer-report of a European expert panel. , 2002, The Lancet. Oncology.

[4]  M. Venturini.  Rational development of capecitabine. , 2002, European journal of cancer.

[5]  C. la Vecchia,et al.  Cancer Mortality in Italy, 1997: Quantifying the Fall in Rates in Women and Men , 2001, Tumori.

[6]  G. Hortobagyi,et al.  Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. , 2001, The oncologist.

[7]  G. Hortobagyi,et al.  Phase I study of vinorelbine and paclitaxel by 3‐hour simultaneous infusion with and without granulocyte colony‐stimulating factor support in metastatic breast carcinoma , 2001, Cancer.

[8]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[9]  V. Lorusso,et al.  Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Klijn,et al.  Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. , 2000, European journal of cancer.

[11]  D. Budman,et al.  Synergism of Cytotoxic Effects of Vinorelbine and Paclitaxel in Vitro , 2000, Cancer investigation.

[12]  A. Amodio,et al.  First-Line Chemotherapy with Vinorelbine and Paclitaxel as Simultaneous Infusion in Advanced Breast Cancer , 2000, Oncology.

[13]  R. Livingston,et al.  Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: high complete response rate in a phase I-II study of doxorubicin-treated patients. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Culine,et al.  Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines. , 1999, International journal of oncology.

[15]  W. Petros,et al.  The addition of paclitaxel to continuous infusion 5-fluorouracil is an active regimen for metastatic breast cancer. , 1998, American journal of clinical oncology.

[16]  C. Hudis,et al.  Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Photiou,et al.  In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines. , 1997, European journal of cancer.

[18]  F. Cavalli,et al.  Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  C. Miller,et al.  Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. , 1995, Journal of the National Cancer Institute.

[20]  H. Gabra,et al.  Continuous 5-fluorouracil in the treatment of breast cancer. , 1994, British Journal of Cancer.

[21]  L. Tomatis,et al.  Cancer Mortality in Italy , 1990, Tumori.

[22]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[23]  R. Rubens,et al.  The clinical course of bone metastases from breast cancer. , 1987, British Journal of Cancer.

[24]  F. Caponigro,et al.  Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer , 2004, Breast Cancer Research and Treatment.

[25]  B. Leone,et al.  Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  E. Díaz-Rubio,et al.  Paclitaxel plus vinorelbine in metastatic breast Ca patients with contraindications to receive anthracyclines. , 1998, Oncology.

[27]  R. Holle,et al.  Experience of a German multicenter study group with ifosfamide in small cell lung cancer. , 1989, Seminars in oncology.

[28]  J. Manfredi,et al.  Taxol: an antimitotic agent with a new mechanism of action. , 1984, Pharmacology & therapeutics.

[29]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.